<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882254</url>
  </required_header>
  <id_info>
    <org_study_id>APOLLO</org_study_id>
    <nct_id>NCT04882254</nct_id>
  </id_info>
  <brief_title>Normothermic Machine Perfusion: an Additional Value for Kidney Transplant Outcomes?</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>Normothermic Machine Perfusion as Additional Value to Hypothermic Machine Perfusion for Kidney Transplant Outcomes. A Single-centre, Open-label, Randomised, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomised, controlled, phase II trial to assess the efficacy of 2 hours&#xD;
      normothermic machine perfusion (NMP) of extended criteria(EC)-DBD (donation after brain&#xD;
      death) and DCD (donation after circulatory death) donor kidneys compared to standard care,&#xD;
      which is hypothermic machine perfusion (HMP) only in the Netherlands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomised to either intervention arm (normothermic machine perfusion, NMP) or standard-of-care (hypothermic machine perfusion, HMP)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with immediate graft function</measure>
    <time_frame>3 months</time_frame>
    <description>Immediate graft function, which is defined as no delayed graft function and/or no primary non-function of the kidney graft.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of delayed graft function</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate (eGFR) trajectory in the first year post-transplant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with biopsy-proven acute rejection (BPAR) within the first year post-transplant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause and death-censored graft survival up to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient survival up to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Kidney Transplant Failure</condition>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Normothermic machine perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normothermic machine perfusion</intervention_name>
    <description>Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.</description>
    <arm_group_label>Normothermic machine perfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  kidney-only transplant&#xD;
&#xD;
          -  renal replacement therapy at time of transplant&#xD;
&#xD;
          -  receiving standard immunosuppression regimen post-transplant.&#xD;
&#xD;
          -  Donation after circulatory death (DCD) Maastricht type III, IV, or V or extended&#xD;
             criteria donation after brain death (DBD) donor kidneys.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pre-emptive at time of transplant&#xD;
&#xD;
          -  receive a multi-organ or dual kidney transplant&#xD;
&#xD;
          -  age donor or recipient below 18 years&#xD;
&#xD;
          -  Maastricht type I and II DCD&#xD;
&#xD;
          -  donor kidneys preserved on static cold storage (SCS)&#xD;
&#xD;
          -  kidneys retrieved after normothermic regional perfusion (NRP)&#xD;
&#xD;
          -  Recipient virtual panel reactive antibodies â‰¥85%&#xD;
&#xD;
          -  Recipient for who it is agreed in advance that dialysis after transplant is required,&#xD;
             such as in the context of hyperoxaluria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erasmus MC Transplant Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Minnee, MD, PhD</last_name>
      <phone>+31107031149</phone>
      <email>r.minnee@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Robert Minnee</investigator_full_name>
    <investigator_title>Transplant surgeon</investigator_title>
  </responsible_party>
  <keyword>Normothermic kidney machine perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

